Advertisement

Virchows Archiv

, Volume 458, Issue 3, pp 363–369 | Cite as

An unusual and potentially misleading phenotypic change in a primary gastrointestinal stromal tumour (GIST) under imatinib mesylate therapy

  • Nikolaos Vassos
  • Abbas AgaimyEmail author
  • Anne Schlabrakowski
  • Werner Hohenberger
  • Regine Schneider-Stock
  • Roland S. Croner
Case Report

Abstract

We present a unique case of a 62-year-old female who was diagnosed with a huge gastric gastrointestinal stromal tumour (GIST). Core needle biopsy revealed a cellular spindle cell GIST with diffuse expression of CD117 and CD34. Four mitotic figures were counted in ten available HPFs, indicating a high-risk tumour. Computed tomography scan, performed after 8 months of neoadjuvant imatinib mesylate treatment (Glivec, 400 mg/day), revealed a partial response with reduction of tumour size from 20 × 15 × 15 cm to 13.3 × 8 × 7.6 cm. The patient underwent complete tumour resection. The tumour revealed extensive cystic changes and hyalinisation in 90% of the tumour mass. Multiple viable tumour clones, measuring up to 1 cm, showed highly anaplastic, large epithelioid cells with vesicular nuclei and prominent, centrally located nucleoli, strikingly mimicking the appearance of proximal-type epithelioid sarcoma, anaplastic carcinoma, melanoma or epithelioid angiosarcoma. These anaplastic tumour cells expressed pankeratin (KL-1) and vimentin, but they were completely negative for CD117, DOG-1, CD34, S100, desmin, α-smooth muscle actin, HMB45, CD30, CD45, CK7, CK20 and 34βE-12. Sufficient tissue for molecular analysis was available from the resected tumour. No mutations were detected in KIT exons 9, 11, 13, 17, PDGFRA exons 12, 14, 18, KRAS and BRAF. The patient was alive with no evidence of recurrence 28 months later. To our knowledge, this represents the first report on this unusual type of trans-differentiation in GIST under imatinib therapy. Awareness of this phenomenon would help to avoid diagnostic confusion when evaluating post-treatment resections from GISTs.

Keywords

GIST Imatinib mesylate KIT Wild-type Neoadjuvant treatment 

Notes

Conflict of interest

The authors declare that they have no disclosures.

References

  1. 1.
    Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23:70–83PubMedCrossRefGoogle Scholar
  2. 2.
    Liegl-Atzwanger B, Fletcher JA, Fletcher CD (2010) Gastrointestinal stromal tumors. Virchows Arch 456:111–127PubMedCrossRefGoogle Scholar
  3. 3.
    Fletcher CD, Berman JJ, Corless C et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–465PubMedCrossRefGoogle Scholar
  4. 4.
    Agaimy A, Wünsch PH, Hofstaedter F et al (2007) Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31:113–120PubMedCrossRefGoogle Scholar
  5. 5.
    Scarpa M, Bertin M, Ruffolo C et al (2008) A systematic review on the clinical diagnosis of gastrointestinal stromal tumors. J Surg Oncol 98:384–392PubMedCrossRefGoogle Scholar
  6. 6.
    Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580PubMedCrossRefGoogle Scholar
  7. 7.
    Lasota J, Miettinen M (2006) KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 23:91–102PubMedCrossRefGoogle Scholar
  8. 8.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056PubMedCrossRefGoogle Scholar
  9. 9.
    Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480PubMedCrossRefGoogle Scholar
  10. 10.
    Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342–4349PubMedCrossRefGoogle Scholar
  11. 11.
    Sciot R, Debiec-Rychter M (2006) GIST under imatinib therapy. Semin Diagn Pathol 23:84–90PubMedCrossRefGoogle Scholar
  12. 12.
    Casali PG, Jost L, Reichardt P et al (2009) Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):64–67PubMedGoogle Scholar
  13. 13.
    Liegl B, Kepten I, Le C et al (2008) Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216:64–74PubMedCrossRefGoogle Scholar
  14. 14.
    Pauwels P, Debiec-Rychter M, Stul M et al (2005) Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 47:41–47PubMedCrossRefGoogle Scholar
  15. 15.
    Bickenbach K, Wilcox R, Veerapong J et al (2007) A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. J Gastrointest Surg 11:758–766PubMedCrossRefGoogle Scholar
  16. 16.
    Liegl B, Hornick JL, Antonescu CR, Corless CL et al (2009) Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am J Surg Pathol 33:218–226PubMedCrossRefGoogle Scholar
  17. 17.
    Agaram NP, Wong GC, Guo T et al (2008) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosom Cancer 47:853–859PubMedCrossRefGoogle Scholar
  18. 18.
    Rossi S, Orvieto E, Furlanetto A et al (2004) Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody. Mod Pathol 17:547–552PubMedCrossRefGoogle Scholar
  19. 19.
    Torihashi S, Nishi K, Tokutomi Y et al (1999) Blockade of kit signaling induces transdifferentiation of interstitial cells of cajal to a smooth muscle phenotype. Gastroenterology 117:140–148PubMedCrossRefGoogle Scholar
  20. 20.
    Janeway KA, Liegl B, Harlow A et al (2007) Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 67:9084–9088PubMedCrossRefGoogle Scholar
  21. 21.
    Duensing A, Medeiros F, McConarty B et al (2004) Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23:3999–4006PubMedCrossRefGoogle Scholar
  22. 22.
    Caruana G, Cambareri AC, Ashman LK (1999) Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts. Oncogene 18:5573–5581PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Nikolaos Vassos
    • 1
  • Abbas Agaimy
    • 2
    Email author
  • Anne Schlabrakowski
    • 2
  • Werner Hohenberger
    • 1
  • Regine Schneider-Stock
    • 2
  • Roland S. Croner
    • 1
  1. 1.Department of SurgeryUniversity HospitalErlangenGermany
  2. 2.Institute of PathologyUniversity HospitalErlangenGermany

Personalised recommendations